查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1944955

結構性心臟封堵器市場（依產品類型、入路方式、材料類型、通路和最終用戶分類），全球預測，2026-2032年

Structural Heart Occlusion Devices Market by Product Type, Access Method, Material Type, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，結構性心臟封堵裝置市場價值將達到 15.3 億美元，到 2026 年將成長至 16.5 億美元，到 2032 年將達到 24.7 億美元，年複合成長率為 7.04%。

關鍵市場統計數據
基準年 2025 15.3億美元
預計年份：2026年 16.5億美元
預測年份 2032 24.7億美元
複合年成長率 (%) 7.04%

權威的導論概述了塑造結構性心臟封堵裝置生態系統的臨床創新、手術促進因素和相關人員的優先事項。

結構性心臟封堵器械領域正經歷著快速的臨床創新、不斷變化的手術方案選擇以及監管機構和支付方日益嚴格的審查。器械材料、導管技術和影像引導技術的進步正逐步拓展心房中膈缺損症室間隔缺損的治療選擇。同時，臨床團隊也擴大在傳統外科手術和微創手術之間進行權衡。因此，決策者必須綜合考慮器械性能、手術複雜性和醫療機構能力，才能為不同患者群體確定最佳治療方案。

技術進步、臨床偏好變化和監管重點的融合正在重塑閉式胸腔外科手術中的器械設計和手術方案選擇。

近年來，結構性心臟疾病治療領域發生了變革性變化，這主要得益於技術、臨床和操作等多方面因素的共同推動。器械材料的改進，特別是精細化的鎳鈦合金支架和新型生物材料塗層，提高了器械的輸送性和內皮化效率；而迭代式設計改進則降低了侵蝕和殘餘分流等不利事件的風險。同時，經導管介入手術技術也日益成熟。影像學技術、導管控制系統以及股動脈入路和經房間隔入路等技術的應用，使得器械定位更加精準，同時減少了透視時間和手術時間。

評估2025年美國關稅調整如何重塑整個閉塞裝置價值鏈的供應鏈決策、籌資策略和採購動態。

2025年美國關稅政策的實施為結構性心臟器械供應鏈中的製造商和醫療系統帶來了新的成本促進因素。進口器械組件和成品關稅的提高導致到岸成本波動，迫使企業重新評估供應商網路。許多製造商正在加快近岸外包的步伐，或探索其他籌資策略，以穩定毛利率並維持價格競爭力。因此，醫院和專科心臟中心的採購團隊不得不重新審視合約條款和庫存政策，以在不影響器械供應的前提下，緩解短期價格波動的影響。

將產品類型、流程存取途徑、終端用戶環境、分銷管道和材料選擇與採用促進因素聯繫起來的策略性細分洞察

精細的細分分析揭示了產品平台、入路方式、臨床終端用戶、分銷網路和材料選擇等方面的戰略意義。基於產品類型，評估重點關注心房中膈缺損症封堵器、卵圓孔未閉合封堵器和室間隔缺損封堵器，每種封堵器都有不同的臨床適應症、解剖學挑戰和封堵器設計權衡。這種產品層面的差異化直接影響手術方案的發展和臨床訓練需求，也是確定供應商洽談中哪些封堵器屬性是優先考慮的差異化因素的關鍵資訊。

區域策略意義：重點闡述監管多樣性、支付方結構和臨床能力對關鍵區域醫療器材普及的影響

區域趨勢差異顯著，影響美洲、歐洲、中東和非洲以及亞太地區各司法管轄區的監管趨勢、報銷方式和手術普及率。在美洲，卓越中心和高容量植入團隊推動了手術普及，他們強調循證器械和精簡的供應鏈。支付方和醫院網路優先考慮成本效益和長期療效，迫使製造商提供可靠的臨床數據和流程效率。同時，在歐洲、中東和非洲，不同的監管環境和報銷機制要求制定個人化的打入市場策略。早期採用者往往聚集在擁有先進影像設備和混合手術室的三級心臟中心周圍。

深入了解決定閉塞裝置製造商商業性成功的競爭定位、合作夥伴關係和價值創造能力

結構性心臟封鎖領域的競爭格局主要體現在差異化的臨床證據、卓越的製造流程以及透過培訓和服務來支持手術團隊的能力。領先的器材開發商正大力投資於完善的臨床項目和上市後註冊研究，以證明其長期安全性並降低醫院納入處方集的門檻。新參與企業和專業工程團隊則專注於研發精密的輸送系統和小型化的器械，以贏得介入醫師的青睞。同時，擁有成熟全球佈局的製造商正利用其分銷網路和臨床教育平台來擴大產品應用範圍。

為領導者加速採納，我們提出了以下實用建議：證據收集、供應鏈韌性、客製化商業模式和全面培訓。

產業領導者應優先考慮多管齊下的策略，將臨床證據的產生、供應鏈的韌性以及有針對性的商業性合作相結合。首先，企業必須投資於嚴謹且可操作的臨床研究和註冊研究，並專注於長期安全性和功能性結果。這些數據資產能夠縮短醫院評估週期，並有助於在採購談判中取得有利結果。其次，透過雙重採購、區域夥伴關係和選擇性近岸外包來增強生產柔軟性，可以降低關稅風險，防止供應中斷，從而維護客戶信心和合約穩定性。

透明的調查方法，詳細說明了主要訪談、二手證據綜合以及為確保研究結果可靠且可操作而採用的三角驗證技術。

為了整體情況了解結構性心臟閉塞的治療方法，我們採用了一種結合結構化一手研究和二手證據綜合的研究方法。一手研究包括對植入醫生、臨床試驗研究人員、醫院採購人員和醫療設備研發主管的訪談，以了解營運挑戰、臨床偏好和商業性需求。二手研究包括對同行評審的臨床文獻、監管附加檔、醫療設備包裝說明書和操作指南進行系統性回顧，以驗證我們的研究結果並檢驗說明。

一項權威的綜合分析證實，臨床證據、供應鏈韌性和執行清晰度之間的相互作用決定了推廣的成功。

總之，結構性心臟封堵器械領域正處於轉折點，材料科學、手術創新和商業性可行性正在融合，並將影響未來臨床應用的發展。臨床醫生和醫療機構領導者必須權衡器材的具體優勢與機構能力和報銷現實，而製造商則必須證明其臨床差異化和運作可靠性。隨著關稅驅動的供應鏈調整、不斷變化的准入方式以及長期證據日益重要性的相互作用，戰略清晰度和卓越的執行力將決定誰能獲得持續的應用。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 結構性心臟封堵器市場（依產品類型分類）

  • 心房中膈缺損症治療裝置
  • 卵圓孔未閉合裝置
  • 室間隔缺損裝置

9. 結構性心臟封堵器市場進入方式分類

  • 外科
    • 微創
    • 開胸手術
  • 經導管
    • 股動脈路徑
    • 經心房中隔入路

10. 結構性心臟封堵器市場（依材料類型分類）

  • 生物材料
  • 鎳鈦諾

11. 結構性心臟封堵器市場依通路分類

  • 直銷
  • 經銷商
  • 線上

12. 結構性心臟封堵器市場（依最終用戶分類）

  • 門診手術中心
  • 醫院
    • 非教育機構
    • 教學醫院
  • 專業心臟中心

13. 各地區結構性心臟封堵器市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

14. 結構性心臟封堵器市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國結構性心臟封堵器市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國結構性心臟封堵器市場

17. 中國結構性心臟封堵器市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Artivion, Inc.
  • Boston Scientific Corporation
  • Braile Biomedica Industria e Comercio de Aparelhos Cirurgicos SA
  • Comed BV
  • Edwards Lifesciences Corporation
  • JenaValve Technology, Inc.
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • LifeTech Scientific Corporation
  • LivaNova PLC
  • Medtronic plc
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort Scientific Corporation
  • Occlutech International AB
  • Shanghai Shape Memory Alloy Co., Ltd.
  • Shenzhen Lifetech Scientific Co., Ltd.
  • Terumo Corporation
  • Venus Medtech（Hangzhou）Inc.
  • WL Gore & Associates, Inc.
Product Code: MRR-F847BD9C7506

The Structural Heart Occlusion Devices Market was valued at USD 1.53 billion in 2025 and is projected to grow to USD 1.65 billion in 2026, with a CAGR of 7.04%, reaching USD 2.47 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.53 billion
Estimated Year [2026] USD 1.65 billion
Forecast Year [2032] USD 2.47 billion
CAGR (%) 7.04%

An authoritative introduction framing the clinical innovations, procedural drivers, and stakeholder priorities shaping the structural heart occlusion device ecosystem

The landscape of structural heart occlusion devices is defined by rapid clinical innovation, shifting procedural preferences, and intensifying scrutiny from regulators and payers. Advances in device materials, catheter technologies, and imaging guidance have progressively expanded options for treating atrial and ventricular septal defects, while clinical teams increasingly weigh minimally invasive approaches against traditional surgical correction. As a result, decision-makers must reconcile device performance, procedural complexity, and institutional capabilities to identify the optimal care pathway for distinct patient cohorts.

Moreover, evolving evidence streams are reshaping adoption curves: robust comparative studies, longer-term follow-up data, and head-to-head procedural analyses now inform multidisciplinary heart team decisions. Thus, stakeholders from implanting physicians to procurement executives need concise syntheses that translate clinical outcomes, access method implications, and user environment constraints into executable strategies. This introduction sets the tone for a focused executive review that clarifies where clinical need, innovation momentum, and commercial opportunity intersect in the structural heart occlusion domain.

Exploration of the converging technological advances, clinical preference shifts, and regulatory emphasis that are reshaping device design and procedural choice in occlusion therapy

Recent transformative shifts in the structural heart occlusion landscape have been driven by converging technological, clinical, and operational forces. Improvements in device materials, particularly the refinement of nitinol frames and novel biomaterial coverings, have enhanced deliverability and endothelialization, while iterative design changes reduce the risk of adverse events such as erosion and residual shunts. Concurrently, the transcatheter procedural toolkit has matured: imaging modalities, catheter control systems, and approaches such as femoral and transseptal access now permit more precise placement with reduced fluoroscopy and shorter procedural times.

In parallel, clinician preferences have shifted toward less invasive options where outcomes and institutional capabilities support them. Minimally invasive surgical techniques and percutaneous transcatheter approaches each retain clear indications, but the balance is tilting as operator experience grows and device profiles shrink. Finally, regulatory emphasis on post-market surveillance and real-world evidence generation has prompted device developers to integrate registry designs and extended follow-up into clinical programs, thereby raising the evidentiary bar and creating pathways for differentiated value propositions based on long-term safety and effectiveness.

Assessment of how the 2025 United States tariff changes have reshaped supply chain decisions, sourcing strategies, and procurement dynamics across the occlusion device value chain

The tariff environment implemented in the United States in 2025 introduced a new layer of cost dynamics for manufacturers and health systems engaged in structural heart device supply chains. Increased duties on imported device components and finished assemblies altered landed costs and forced re-evaluation of supplier networks, with many manufacturers accelerating nearshoring efforts or seeking alternate sourcing strategies to stabilize gross margins and preserve price competitiveness. Consequently, procurement teams in hospitals and specialty cardiac centers have had to reexamine contract terms and inventory policies to mitigate short-term pricing volatility while ensuring uninterrupted device availability.

Over time, these trade policy changes also affected strategic partnerships and manufacturing footprints. Some device makers pursued localized manufacturing partnerships to avoid tariff exposure and to enhance responsiveness to customer needs, whereas others absorbed costs or restructured product portfolios to maintain access. The resulting supply chain reconfiguration prioritized supplier redundancy, qualified domestic sources for critical components, and invested in quality systems to expedite regulatory qualification. Clinicians and hospital administrators have watched these shifts closely because supply continuity and device affordability directly influence procedural scheduling, patient access, and the feasibility of adopting newer device iterations.

Strategic segmentation insights tying product categories, procedural access routes, end user environments, distribution channels, and material choices to adoption drivers

A refined segmentation view exposes strategic implications across product platforms, access methods, clinical end users, distribution networks, and material selection. Based on product type, evaluation focuses on atrial septal defect devices, patent foramen ovale devices, and ventricular septal defect devices, each presenting distinct clinical indications, anatomical challenges, and device design trade-offs. This product-level differentiation directly influences procedural planning and clinical training needs, and it informs which device attributes become priority differentiators in supplier conversations.

Based on access method, the market differentiates between surgical and transcatheter pathways. Surgical approaches still encompass both minimally invasive and open heart techniques, with minimally invasive methods reducing recovery times but requiring specific institutional capabilities. The transcatheter category splits into femoral approach and transseptal approach strategies, each carrying unique catheterization skills, imaging requirements, and patient selection criteria. Based on end user, adoption and procurement dynamics change across ambulatory surgical centers, hospitals, and specialty cardiac centers; within hospitals, distinctions between non-teaching and teaching institutions drive differences in case mix, clinical training pipelines, and willingness to adopt novel devices. Based on distribution channel, success depends on direct sales, distributor relationships, and growing online channels for consumables and ancillary equipment, each offering different margins, service expectations, and listing requirements. Finally, based on material type, outcomes and durability considerations pivot between biomaterial and nitinol selections, which dictate manufacturing constraints, regulatory test programs, and clinician perceptions regarding long-term biocompatibility. Taken together, these segmentation lenses illuminate where commercial focus, clinical education, and reimbursement efforts should be concentrated to maximize clinical uptake and institutional alignment.

Regional strategic implications highlighting how regulatory diversity, payer structures, and clinical capacities influence device adoption across major world regions

Regional dynamics vary markedly and influence regulatory trajectories, reimbursement approaches, and procedural adoption rates across Americas, Europe, Middle East & Africa, and Asia-Pacific jurisdictions. In the Americas, institutional adoption has been driven by centers of excellence and high-volume implanting teams that value evidence-backed devices and streamlined supply chains; payers and hospital networks emphasize cost-effectiveness and long-term outcomes, prompting manufacturers to present durable clinical data and pathway efficiencies. Meanwhile, in Europe, Middle East & Africa, regulatory heterogeneity and varied reimbursement environments require tailored market entry strategies, with early adopters often clustered around tertiary cardiac centers that can support advanced imaging and hybrid operating rooms.

Across Asia-Pacific, rapid modernization of cardiovascular services, expanding device-capable hospital networks, and strong investment in interventional cardiology training have created significant demand for adaptable device platforms and scalable training programs. Regional manufacturers and contract manufacturers also play an increasing role in localized supply chains, offering cost advantages and proximity that support faster market responsiveness. Consequently, commercial plans must recognize these geographic distinctions by aligning clinical evidence generation, regulatory pathways, and distribution models with the operational realities and procurement priorities of each region.

Insights into competitive positioning, collaborative partnerships, and value-driving capabilities that determine commercial success among occlusion device manufacturers

Competitive dynamics within the structural heart occlusion space center on differentiated clinical evidence, manufacturing excellence, and the ability to support procedural teams through training and service. Leading device developers invest in robust clinical programs and post-market registries to demonstrate long-term safety profiles and to reduce barriers to hospital formulary inclusion. New entrants and specialized engineering teams focus on refined delivery systems and reduced device profiles to win preference among high-volume interventionalists, while manufacturers with established global footprints leverage distribution networks and clinical education platforms to scale adoption.

In addition, partnerships between device companies and imaging, navigation, or digital health firms are becoming more frequent, as integrated procedural ecosystems deliver measurable workflow improvements and reduce cognitive load for operators. Supply chain partnerships and contract manufacturing agreements also influence competitive positioning by enabling faster iterative development and cost control. Ultimately, companies that combine clear clinical differentiation with reliable supply, targeted training, and responsive customer support tend to secure stronger institutional relationships and more predictable utilization patterns.

Actionable recommendations for leaders emphasizing evidence generation, supply resilience, tailored commercial models, and integrated training to accelerate adoption

Industry leaders should prioritize a multi-pronged strategy that aligns clinical evidence generation, supply chain resilience, and targeted commercial engagement. First, companies must invest in rigorous, pragmatic clinical studies and registries that emphasize long-term safety and functional outcomes; these data assets shorten hospital evaluation cycles and support favorable procurement discussions. Second, strengthening manufacturing flexibility-through dual sourcing, regional partnerships, or selective nearshoring-reduces tariff exposure and protects against supply disruptions, thereby preserving customer trust and contract stability.

Third, tailored commercial models are essential: direct-sales engagement works well with high-touch institutional customers, while distributor and online channels can extend reach for consumables and supplementary items. Training and proctoring programs should be integrated into launch plans to accelerate operator proficiency with specific access methods such as femoral or transseptal approaches, and to support minimally invasive surgical workflows where appropriate. Lastly, embedding health economics and value demonstration into market access strategies will resonate with hospitals and payers that prioritize procedural efficiency and long-term outcomes; this approach should include real-world evidence packages and case-mix analyses that demonstrate comparative advantage for specific patient populations.

Transparent research methodology detailing primary interviews, secondary evidence synthesis, and triangulation techniques used to ensure robust and actionable insights

The research approach combined structured primary engagement with secondary evidence synthesis to produce a holistic view of the structural heart occlusion landscape. Primary research included interviews with implanting physicians, clinical trial investigators, hospital procurement leaders, and device development executives to capture operational challenges, clinical preferences, and commercial needs. Secondary research comprised systematic review of peer-reviewed clinical literature, regulatory filings, device labeling, and procedural guidelines to triangulate findings and validate clinical performance narratives.

Data triangulation was used to reconcile differing perspectives and to surface consistent themes across respondent segments. The methodology also incorporated analysis of supply chain documentation and reimbursement policy materials to assess operational and market access constraints. Quality control steps included cross-validation of interview findings, audit of secondary-source citations, and iterative review cycles with clinical advisors to ensure accuracy and relevance of device performance and procedural implications.

A conclusive synthesis underscoring the interplay of clinical evidence, supply chain resilience, and executional clarity that will determine adoption success

In conclusion, the structural heart occlusion device arena is at an inflection point where material science, procedural innovation, and commercial execution converge to shape near-term clinical adoption. Clinicians and health system leaders must weigh device-specific benefits against institutional capabilities and reimbursement realities, while manufacturers must demonstrate both clinical differentiation and operational reliability. The interplay of tariff-driven supply chain adjustments, evolving access methods, and the increasing importance of long-term evidence means that strategic clarity and executional excellence will determine who captures durable adoption.

Moving forward, stakeholders who integrate rigorous clinical data, resilient sourcing strategies, and focused training programs will be best positioned to translate innovation into routine care. Decision-makers should therefore prioritize investments that reduce procedural friction, secure supply continuity, and demonstrate measurable patient benefit to accelerate acceptance among multidisciplinary heart teams.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Structural Heart Occlusion Devices Market, by Product Type

  • 8.1. Atrial Septal Defect Devices
  • 8.2. Patent Foramen Ovale Devices
  • 8.3. Ventricular Septal Defect Devices

9. Structural Heart Occlusion Devices Market, by Access Method

  • 9.1. Surgical
    • 9.1.1. Minimally Invasive
    • 9.1.2. Open Heart
  • 9.2. Transcatheter
    • 9.2.1. Femoral Approach
    • 9.2.2. Transseptal Approach

10. Structural Heart Occlusion Devices Market, by Material Type

  • 10.1. Biomaterial
  • 10.2. Nitinol

11. Structural Heart Occlusion Devices Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Distributors
  • 11.3. Online

12. Structural Heart Occlusion Devices Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Hospitals
    • 12.2.1. Non-Teaching
    • 12.2.2. Teaching
  • 12.3. Specialty Cardiac Centers

13. Structural Heart Occlusion Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Structural Heart Occlusion Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Structural Heart Occlusion Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Structural Heart Occlusion Devices Market

17. China Structural Heart Occlusion Devices Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Artivion, Inc.
  • 18.7. Boston Scientific Corporation
  • 18.8. Braile Biomedica Industria e Comercio de Aparelhos Cirurgicos S.A.
  • 18.9. Comed B.V.
  • 18.10. Edwards Lifesciences Corporation
  • 18.11. JenaValve Technology, Inc.
  • 18.12. Lepu Medical Technology (Beijing) Co., Ltd.
  • 18.13. LifeTech Scientific Corporation
  • 18.14. LivaNova PLC
  • 18.15. Medtronic plc
  • 18.16. Meril Life Sciences Pvt. Ltd.
  • 18.17. MicroPort Scientific Corporation
  • 18.18. Occlutech International AB
  • 18.19. Shanghai Shape Memory Alloy Co., Ltd.
  • 18.20. Shenzhen Lifetech Scientific Co., Ltd.
  • 18.21. Terumo Corporation
  • 18.22. Venus Medtech (Hangzhou) Inc.
  • 18.23. W. L. Gore & Associates, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY ACCESS METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY ATRIAL SEPTAL DEFECT DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY ATRIAL SEPTAL DEFECT DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY ATRIAL SEPTAL DEFECT DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY PATENT FORAMEN OVALE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY PATENT FORAMEN OVALE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY PATENT FORAMEN OVALE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY VENTRICULAR SEPTAL DEFECT DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY VENTRICULAR SEPTAL DEFECT DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY VENTRICULAR SEPTAL DEFECT DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY ACCESS METHOD, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY SURGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY SURGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY SURGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY OPEN HEART, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY OPEN HEART, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY OPEN HEART, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY TRANSCATHETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY TRANSCATHETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY TRANSCATHETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY FEMORAL APPROACH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY FEMORAL APPROACH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY FEMORAL APPROACH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY TRANSSEPTAL APPROACH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY TRANSSEPTAL APPROACH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY TRANSSEPTAL APPROACH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY BIOMATERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY BIOMATERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY BIOMATERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY NITINOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY NITINOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY NITINOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY NON-TEACHING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY NON-TEACHING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY NON-TEACHING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY TEACHING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY TEACHING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY TEACHING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY SPECIALTY CARDIAC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY SPECIALTY CARDIAC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY SPECIALTY CARDIAC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY ACCESS METHOD, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY ACCESS METHOD, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY ACCESS METHOD, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY ACCESS METHOD, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY ACCESS METHOD, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY ACCESS METHOD, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY ACCESS METHOD, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY ACCESS METHOD, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY ACCESS METHOD, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 150. GCC STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GCC STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. GCC STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY ACCESS METHOD, 2018-2032 (USD MILLION)
  • TABLE 153. GCC STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 154. GCC STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 155. GCC STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. GCC STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. GCC STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GCC STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY ACCESS METHOD, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY ACCESS METHOD, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 177. G7 STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. G7 STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. G7 STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY ACCESS METHOD, 2018-2032 (USD MILLION)
  • TABLE 180. G7 STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 181. G7 STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 182. G7 STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. G7 STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. G7 STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. G7 STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 186. NATO STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. NATO STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. NATO STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY ACCESS METHOD, 2018-2032 (USD MILLION)
  • TABLE 189. NATO STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 190. NATO STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 191. NATO STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. NATO STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. NATO STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. NATO STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY ACCESS METHOD, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY ACCESS METHOD, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY TRANSCATHETER, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA STRUCTURAL HEART OCCLUSION DEVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)